ArticleFrontiers in immunology2022

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.

Jiaying Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.